Cancers & treatments·Regimen libraryFirst line

Doxorubicin

Checked 2026-09-09

Advanced soft-tissue sarcoma, first line

One cycle

every 21 days × 6 · about 18 weeks in total

21-day cycle × 6 (cumulative dose 450 mg/m²) (about 18 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Doxorubicin Cytotoxic chemotherapy (anthracycline)	75 mg/m²	IV	D1

Cycles

6 (cumulative dose 450 mg/m²)

21-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Consider (10-20% FN risk)

Notes

Doxorubicin + ifosfamide (AIM) adds response rate but not survival; reserve for symptomatic bulk or neoadjuvant use (ISG-STS 1001).

Used in

Sarcomas (soft tissue, bone, GIST)

Products

Doxorubicin

Source

EORTC 62012, Lancet Oncology 2014

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Eribulin

Metastatic breast cancer after an anthracycline and a taxane; liposarcoma

every 21 days

Trabectedin

Liposarcoma and leiomyosarcoma after an anthracycline

every 21 days

All regimens Trabectedin →